Universal Beteiligungs und Servicegesellschaft mbH Makes New $381,000 Investment in Savara Inc. (NASDAQ:SVRA)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH invested approximately $381,000 to acquire a new stake in Savara Inc., acquiring 137,694 shares, reflecting only 0.08% of the total shares at the end of the reporting period.
• Other institutional investors have also increased their stakes in Savara, with Vanguard Group Inc. owning over $25 million and JPMorgan Chase & Co. growing their stake by nearly 2,000% in the last quarter.
• Savara is a clinical-stage pharmaceutical company focusing on treatments for rare respiratory diseases, and it reported earnings per share of ($0.12) in its last quarterly earnings, meeting analysts' expectations.

Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Savara Inc. (NASDAQ:SVRA - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 137,694 shares of the company's stock, valued at approximately $381,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.08% of Savara at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Savara by 4.6% in the 4th quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company's stock worth $25,512,000 after buying an additional 365,959 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Savara by 24.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 156,983 shares of the company's stock valued at $482,000 after purchasing an additional 31,168 shares during the last quarter. Millennium Management LLC grew its position in Savara by 71.8% during the fourth quarter. Millennium Management LLC now owns 482,263 shares of the company's stock valued at $1,481,000 after buying an additional 201,599 shares during the period. Deutsche Bank AG grew its stake in Savara by 6.1% during the fourth quarter. Deutsche Bank AG now owns 927,595 shares of the company's stock valued at $2,848,000 after acquiring an additional 53,054 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its stake in Savara by 314.7% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 70,560 shares of the company's stock worth $217,000 after purchasing an additional 53,547 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company's stock.

Savara Stock Down 4.2%

NASDAQ:SVRA traded down $0.12 during mid-day trading on Thursday, hitting $2.63. 302,422 shares of the company's stock were exchanged, compared to its average volume of 1,214,837. The company has a debt-to-equity ratio of 0.20, a current ratio of 14.91 and a quick ratio of 14.91. The company has a market cap of $453.70 million, a PE ratio of -5.45 and a beta of 0.40. Savara Inc. has a one year low of $1.89 and a one year high of $4.70. The business has a fifty day moving average price of $2.33 and a 200 day moving average price of $2.66.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). Equities analysts predict that Savara Inc. will post -0.45 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Guggenheim reissued a "buy" rating and set a $8.00 target price (down from $9.00) on shares of Savara in a research note on Wednesday, May 28th. HC Wainwright downgraded Savara from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $6.00 to $2.00 in a research note on Thursday, May 29th. Wells Fargo & Company reduced their target price on shares of Savara from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Wednesday, May 28th. Finally, Evercore ISI lowered their price target on Savara from $3.00 to $2.00 and set an "in-line" rating on the stock in a research report on Wednesday, May 28th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Savara presently has an average rating of "Moderate Buy" and a consensus price target of $5.60.

Insider Buying and Selling

In related news, Director Richard J. Hawkins bought 48,225 shares of the stock in a transaction on Friday, June 20th. The shares were bought at an average cost of $2.04 per share, for a total transaction of $98,379.00. Following the purchase, the director owned 115,466 shares of the company's stock, valued at $235,550.64. This trade represents a 71.72% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 5.33% of the stock is owned by company insiders.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.